PL1771455T3 - Produkty degradacji oksydacyjnej atorwastatyny wapniowej - Google Patents

Produkty degradacji oksydacyjnej atorwastatyny wapniowej

Info

Publication number
PL1771455T3
PL1771455T3 PL05760907.5T PL05760907T PL1771455T3 PL 1771455 T3 PL1771455 T3 PL 1771455T3 PL 05760907 T PL05760907 T PL 05760907T PL 1771455 T3 PL1771455 T3 PL 1771455T3
Authority
PL
Poland
Prior art keywords
degradation products
oxidative degradation
atorvastatin calcium
atorvastatin
calcium
Prior art date
Application number
PL05760907.5T
Other languages
English (en)
Inventor
Rok Grahek
Darko Kocjan
Andrej Bastarda
Andrej Kocijan
Matjaz Kracun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1771455(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL1771455T3 publication Critical patent/PL1771455T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL05760907.5T 2004-07-16 2005-07-15 Produkty degradacji oksydacyjnej atorwastatyny wapniowej PL1771455T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400209 2004-07-16
SI200400348 2004-12-24

Publications (1)

Publication Number Publication Date
PL1771455T3 true PL1771455T3 (pl) 2016-11-30

Family

ID=35457712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05760907.5T PL1771455T3 (pl) 2004-07-16 2005-07-15 Produkty degradacji oksydacyjnej atorwastatyny wapniowej

Country Status (14)

Country Link
US (4) US8044086B2 (pl)
EP (1) EP1771455B1 (pl)
JP (1) JP5000502B2 (pl)
CN (1) CN1997651B (pl)
AU (1) AU2005263550C1 (pl)
BR (1) BRPI0513396A (pl)
CA (2) CA2833770A1 (pl)
ES (1) ES2586561T3 (pl)
HU (1) HUE029911T2 (pl)
MX (1) MX2007000582A (pl)
PL (1) PL1771455T3 (pl)
RU (1) RU2412191C2 (pl)
SI (1) SI1771455T1 (pl)
WO (1) WO2006008091A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321132B (en) 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IS8607A (is) * 2007-02-09 2008-08-10 Actavis Group Hf. Stöðugar atorvastatin samsetningar
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
CN110646550B (zh) * 2018-06-26 2022-12-02 北京伟林恒昌医药科技有限公司 一种阿托伐他汀钙中有关物质的检测方法
CN115754025A (zh) * 2021-09-02 2023-03-07 上虞京新药业有限公司 一种匹伐他汀钙中基因毒性杂质gt1的检测方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3114497A (en) * 1962-05-18 1963-12-17 Kugler Emanuel Drawstring bag
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ294108B6 (cs) * 1995-07-17 2004-10-13 Warner@Lambertácompany Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
KR100668575B1 (ko) * 1997-12-19 2007-01-17 워너-램버트 익스포트 리미티드 1,3-디올의 합성방법
IN191236B (pl) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
AU780624B2 (en) 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
WO2001037876A2 (en) 1999-11-24 2001-05-31 Bayer Aktiengesellschaft Methods of ameliorating abnormal bone states
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
EP1584616A1 (en) * 1999-12-17 2005-10-12 Pfizer Science and Technology Ireland Limited Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
IL149088A0 (en) * 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A process for producing crystalline atorvastatin calcium
JP2003518038A (ja) * 1999-12-20 2003-06-03 ニコラス， ジェイ カークホフ， 流動床噴霧乾燥によるナノ粒子製造方法
CA2399396A1 (en) 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors
KR100704213B1 (ko) * 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
KR100877165B1 (ko) * 2000-11-16 2009-01-07 테바 파마슈티컬 인더스트리즈 리미티드 수산화 칼슘을 이용한[Ｒ(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산 에스테르의 가수분해
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622697A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
PL368647A1 (pl) 2001-07-30 2005-04-04 Dr.Reddy's Laboratories Ltd. Krystaliczne Formy VI i VII soli wapniowej atorwastatyny
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
PL372241A1 (pl) * 2002-02-19 2005-07-11 Teva Pharmaceutical Industries Ltd. Sposób desolwatacji solwatów soli hemi-wapniowej atorwastatyny i sól hemi-wapniowa atorwastatyny wolna od rozpuszczalnika organicznego
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
ES2381473T3 (es) * 2004-03-17 2012-05-28 Ranbaxy Laboratories Limited Procedimiento para la preparación de atorvastatina cálcica en forma amorfa

Also Published As

Publication number Publication date
CA2573969C (en) 2014-02-04
US8044086B2 (en) 2011-10-25
US20070208071A1 (en) 2007-09-06
RU2412191C2 (ru) 2011-02-20
RU2007105689A (ru) 2008-08-27
US20100219063A1 (en) 2010-09-02
JP2008506655A (ja) 2008-03-06
CA2573969A1 (en) 2006-01-26
CA2833770A1 (en) 2006-01-26
ES2586561T3 (es) 2016-10-17
AU2005263550B2 (en) 2011-11-03
JP5000502B2 (ja) 2012-08-15
EP1771455B1 (en) 2016-05-11
US9453030B2 (en) 2016-09-27
MX2007000582A (es) 2007-03-30
CN1997651A (zh) 2007-07-11
CN1997651B (zh) 2012-06-06
HUE029911T2 (en) 2017-04-28
AU2005263550C1 (en) 2013-01-17
BRPI0513396A (pt) 2008-05-06
WO2006008091A2 (en) 2006-01-26
WO2006008091A3 (en) 2006-09-08
US20100056605A1 (en) 2010-03-04
EP1771455A2 (en) 2007-04-11
AU2005263550A1 (en) 2006-01-26
US20150105551A1 (en) 2015-04-16
SI1771455T1 (sl) 2016-09-30

Similar Documents

Publication Publication Date Title
IL187331A0 (en) Terminal sterilization of injectable collagen products
IL182815A0 (en) Food product
EP1814541A4 (en) STABLE ATORVASTATIN FORMULATIONS
PL1771455T3 (pl) Produkty degradacji oksydacyjnej atorwastatyny wapniowej
ZA200804292B (en) Calcium fortified food product and additive
ZA200701527B (en) Composition comprising statin
EP1793815A4 (en) AMORPHES ATORVASTATINCALCIUM
ZA200608311B (en) Composition comprising statins
EP1886689A4 (en) INHIBITOR OF OXIDATIVE STRESS
GB0521261D0 (en) Prepartaion of bone material
EP1838159A4 (en) FROZEN PRODUCT
GB0412074D0 (en) Combination product
EP1928827A4 (en) PYRROLE DERIVATIVES AS THERAPEUTIC AGENTS
EP1753299A4 (en) FOOD PRODUCT
GB0412584D0 (en) Composition of matter
ZA200610214B (en) Oxidative degradation products of atorvastatin calcium
EP1725527A4 (en) IMPROVED MANUFACTURE OF ATORVASTATIN
GB0519833D0 (en) Treatment of putrescible cakes
GB2417230B (en) Manufacture of packaged stabilized foodstuffs
GB0406228D0 (en) Product
ZAA200500315S (en) Foodstuffs
GB0320838D0 (en) Disinfection of foodstuffs
GB0413732D0 (en) Histone modification
GB0502083D0 (en) Bioactive compounds
GB0424159D0 (en) Product